{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+I+Ovarian+Cancer+AJCC+v8", "query": { "condition": "Stage I Ovarian Cancer AJCC v8" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 25, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+I+Ovarian+Cancer+AJCC+v8&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T02:20:17.364Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02650986", "title": "Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Fallopian Tube Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Ovarian Carcinoma", "Advanced Primary Peritoneal Carcinoma", "Advanced Synovial Sarcoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Fallopian Tube Carcinoma", "Metastatic Melanoma", "Metastatic Ovarian Carcinoma", "Metastatic Primary Peritoneal Carcinoma", "Metastatic Synovial Sarcoma", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Stage III Fallopian Tube Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Primary Peritoneal Cancer AJCC v8", "Stage IIIA Fallopian Tube Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Primary Peritoneal Cancer AJCC v8", "Stage IIIA1 Fallopian Tube Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Fallopian Tube Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Fallopian Tube Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Primary Peritoneal Cancer AJCC v8", "Stage IIIC Fallopian Tube Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Primary Peritoneal Cancer AJCC v8", "Stage IV Fallopian Tube Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Primary Peritoneal Cancer AJCC v8", "Stage IVA Fallopian Tube Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Primary Peritoneal Cancer AJCC v8", "Stage IVB Fallopian Tube Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Primary Peritoneal Cancer AJCC v8", "Unresectable Melanoma", "Unresectable Ovarian Carcinoma", "Unresectable Synovial Sarcoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 15, "start_date": "2017-07-14", "completion_date": "2032-07-14", "has_results": true, "last_update_posted_date": "2025-06-17", "last_synced_at": "2026-05-22T02:20:17.364Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02650986" }, { "nct_id": "NCT00897442", "title": "Collecting Tumor Samples From Patients With Gynecological Tumors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Borderline Ovarian Clear Cell Tumor", "Borderline Ovarian Serous Tumor", "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Cervical Small Cell Carcinoma", "Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Childhood Embryonal Rhabdomyosarcoma", "Childhood Malignant Ovarian Germ Cell Tumor", "Endometrioid Stromal Sarcoma", "Gestational Trophoblastic Tumor", "Malignant Mesothelioma", "Malignant Ovarian Epithelial Tumor", "Melanoma", "Neoplasm of Uncertain Malignant Potential", "Ovarian Brenner Tumor", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Serous Cystadenocarcinoma", "Paget Disease of the Vulva", "Recurrent Cervical Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Recurrent Vaginal Carcinoma", "Recurrent Vulvar Carcinoma", "Stage I Ovarian Cancer", "Stage I Uterine Corpus Cancer", "Stage I Vaginal Cancer", "Stage I Vulvar Cancer", "Stage IA Cervical Cancer", "Stage IA Fallopian Tube Cancer", "Stage IA Ovarian Cancer", "Stage IA Ovarian Germ Cell Tumor", "Stage IB Cervical Cancer", "Stage IB Fallopian Tube Cancer", "Stage IB Ovarian Cancer", "Stage IB Ovarian Germ Cell Tumor", "Stage IC Fallopian Tube Cancer", "Stage IC Ovarian Cancer", "Stage IC Ovarian Germ Cell Tumor", "Stage II Ovarian Cancer", "Stage II Uterine Corpus Cancer", "Stage II Vaginal Cancer", "Stage II Vulvar Cancer", "Stage IIA Cervical Cancer", "Stage IIA Fallopian Tube Cancer", "Stage IIA Ovarian Cancer", "Stage IIA Ovarian Germ Cell Tumor", "Stage IIB Cervical Cancer", "Stage IIB Fallopian Tube Cancer", "Stage IIB Ovarian Cancer", "Stage IIB Ovarian Germ Cell Tumor", "Stage IIC Fallopian Tube Cancer", "Stage IIC Ovarian Cancer", "Stage IIC Ovarian Germ Cell Tumor", "Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor", "Stage III Cervical Cancer", "Stage III Uterine Corpus Cancer", "Stage III Vaginal Cancer", "Stage III Vulvar Cancer", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Ovarian Germ Cell Tumor", "Stage IIIA Primary Peritoneal Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Ovarian Germ Cell Tumor", "Stage IIIB Primary Peritoneal Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Ovarian Germ Cell Tumor", "Stage IIIC Primary Peritoneal Cancer", "Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Cancer", "Stage IV Primary Peritoneal Cancer", "Stage IV Uterine Corpus Cancer", "Stage IVA Cervical Cancer", "Stage IVA Vaginal Cancer", "Stage IVB Cervical Cancer", "Stage IVB Vaginal Cancer", "Stage IVB Vulvar Cancer", "Uterine Corpus Cancer", "Uterine Corpus Leiomyosarcoma", "Vulvar Squamous Cell Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 275, "start_date": "1992-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-10-28", "last_synced_at": "2026-05-22T02:20:17.364Z", "location_count": 187, "location_summary": "Fayetteville, Arkansas • Little Rock, Arkansas • Burbank, California + 128 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Burbank", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00897442" }, { "nct_id": "NCT05276973", "title": "Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube High Grade Serous Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Primary Peritoneal Endometrioid Adenocarcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma", "Stage III Fallopian Tube Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Primary Peritoneal Cancer AJCC v8", "Stage IV Fallopian Tube Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Primary Peritoneal Cancer AJCC v8", "Unresectable Fallopian Tube Endometrioid Adenocarcinoma", "Unresectable Fallopian Tube High Grade Serous Adenocarcinoma", "Unresectable Ovarian Endometrioid Adenocarcinoma", "Unresectable Ovarian High Grade Serous Adenocarcinoma", "Unresectable Primary Peritoneal Endometrioid Adenocarcinoma", "Unresectable Primary Peritoneal High Grade Serous Adenocarcinoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 25, "start_date": "2022-09-08", "completion_date": "2026-02-26", "has_results": true, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-05-22T02:20:17.364Z", "location_count": 8, "location_summary": "San Francisco, California • Augusta, Georgia • Cleveland, Ohio + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05276973" }, { "nct_id": "NCT01366183", "title": "Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Stage I Ovarian Cancer AJCC v6 and v7", "Stage IA Fallopian Tube Cancer AJCC v6 and v7", "Stage IB Fallopian Tube Cancer AJCC v6 and v7", "Stage IC Fallopian Tube Cancer AJCC v6 and v7", "Stage II Ovarian Cancer AJCC v6 and v7", "Stage IIA Fallopian Tube Cancer AJCC v6 and v7", "Stage IIB Fallopian Tube Cancer AJCC v6 and v7", "Stage IIC Fallopian Tube Cancer AJCC v6 and v7", "Stage III Ovarian Cancer AJCC v6 and v7", "Stage III Primary Peritoneal Cancer AJCC v7", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7" ], "interventions": [ { "name": "Assessment of Therapy Complications", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "75 Years", "maximum_age": null, "sex": "ALL", "summary": "75 Years and older" }, "enrollment_count": 290, "start_date": "2011-08-15", "completion_date": null, "has_results": false, "last_update_posted_date": "2021-09-30", "last_synced_at": "2026-05-22T02:20:17.364Z", "location_count": 357, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 245 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01366183" }, { "nct_id": "NCT04501913", "title": "Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8", "Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage 0 Gastric Cancer AJCC v8", "Clinical Stage I Esophageal Adenocarcinoma AJCC v8", "Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage I Gastric Cancer AJCC v8", "Clinical Stage II Esophageal Adenocarcinoma AJCC v8", "Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage II Gastric Cancer AJCC v8", "Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIA Gastric Cancer AJCC v8", "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIB Gastric Cancer AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IVB Gastric Cancer AJCC v8", "Hepatobiliary Neoplasm", "Malignant Digestive System Neoplasm", "Malignant Female Reproductive System Neoplasm", "Malignant Genitourinary System Neoplasm", "Malignant Neoplasm", "Pathologic Stage 0 Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage 0 Gastric Cancer AJCC v8", "Pathologic Stage I Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage I Gastric Cancer AJCC v8", "Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IA Gastric Cancer AJCC v8", "Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IB Gastric Cancer AJCC v8", "Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage II Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage II Gastric Cancer AJCC v8", "Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IIA Gastric Cancer AJCC v8", "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IIB Gastric Cancer AJCC v8", "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage III Gastric Cancer AJCC v8", "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IIIA Gastric Cancer AJCC v8", "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IIIB Gastric Cancer AJCC v8", "Pathologic Stage IIIC Gastric Cancer AJCC v8", "Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IV Gastric Cancer AJCC v8", "Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Stage 0 Colorectal Cancer AJCC v8", "Stage 0a Bladder Cancer AJCC v8", "Stage 0is Bladder Cancer AJCC v8", "Stage I Bladder Cancer AJCC v8", "Stage I Cervical Cancer AJCC v8", "Stage I Colorectal Cancer AJCC v8", "Stage I Ovarian Cancer AJCC v8", "Stage I Prostate Cancer AJCC v8", "Stage I Renal Cell Cancer AJCC v8", "Stage I Uterine Corpus Cancer AJCC v8", "Stage IA Cervical Cancer AJCC v8", "Stage IA Ovarian Cancer AJCC v8", "Stage IA Uterine Corpus Cancer AJCC v8", "Stage IA1 Cervical Cancer AJCC v8", "Stage IA2 Cervical Cancer AJCC v8", "Stage IB Cervical Cancer AJCC v8", "Stage IB Ovarian Cancer AJCC v8", "Stage IB Uterine Corpus Cancer AJCC v8", "Stage IB1 Cervical Cancer AJCC v8", "Stage IB2 Cervical Cancer AJCC v8", "Stage IC Ovarian Cancer AJCC v8", "Stage II Bladder Cancer AJCC v8", "Stage II Cervical Cancer AJCC v8", "Stage II Colorectal Cancer AJCC v8", "Stage II Ovarian Cancer AJCC v8", "Stage II Prostate Cancer AJCC v8", "Stage II Renal Cell Cancer AJCC v8", "Stage II Uterine Corpus Cancer AJCC v8", "Stage IIA Cervical Cancer AJCC v8", "Stage IIA Colorectal Cancer AJCC v8", "Stage IIA Ovarian Cancer AJCC v8", "Stage IIA Prostate Cancer AJCC v8", "Stage IIA1 Cervical Cancer AJCC v8", "Stage IIA2 Cervical Cancer AJCC v8", "Stage IIB Cervical Cancer AJCC v8", "Stage IIB Colorectal Cancer AJCC v8", "Stage IIB Ovarian Cancer AJCC v8", "Stage IIB Prostate Cancer AJCC v8", "Stage IIC Colorectal Cancer AJCC v8", "Stage IIC Prostate Cancer AJCC v8", "Stage III Bladder Cancer AJCC v8", "Stage III Cervical Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage III Uterine Corpus Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8", "Stage IIIA Cervical Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Prostate Cancer AJCC v8", "Stage IIIA Uterine Corpus Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Bladder Cancer AJCC v8", "Stage IIIB Cervical Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Prostate Cancer AJCC v8", "Stage IIIB Uterine Corpus Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Prostate Cancer AJCC v8", "Stage IIIC Uterine Corpus Cancer AJCC v8", "Stage IIIC1 Uterine Corpus Cancer AJCC v8", "Stage IIIC2 Uterine Corpus Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Uterine Corpus Cancer AJCC v8", "Stage IVA Bladder Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVA Uterine Corpus Cancer AJCC v8", "Stage IVB Bladder Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Patient Monitoring", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2019-12-24", "completion_date": "2025-10-17", "has_results": false, "last_update_posted_date": "2025-12-05", "last_synced_at": "2026-05-22T02:20:17.364Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04501913" }, { "nct_id": "NCT03198286", "title": "Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage I Breast Cancer", "Stage I Cervical Cancer", "Stage I Ovarian Cancer", "Stage I Uterine Corpus Cancer", "Stage IA Breast Cancer", "Stage IA Cervical Cancer", "Stage IA Ovarian Cancer", "Stage IA Uterine Corpus Cancer", "Stage IB Breast Cancer", "Stage IB Cervical Cancer", "Stage IB Ovarian Cancer", "Stage IB Uterine Corpus Cancer", "Stage IC Ovarian Cancer", "Stage II Breast Cancer", "Stage II Cervical Cancer", "Stage II Ovarian Cancer", "Stage II Uterine Corpus Cancer", "Stage IIA Breast Cancer", "Stage IIA Cervical Cancer", "Stage IIA Ovarian Cancer", "Stage IIB Breast Cancer", "Stage IIB Cervical Cancer", "Stage IIB Ovarian Cancer", "Stage IIC Ovarian Cancer", "Stage III Breast Cancer", "Stage III Cervical Cancer", "Stage III Ovarian Cancer", "Stage III Uterine Corpus Cancer", "Stage IIIA Breast Cancer", "Stage IIIA Cervical Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Uterine Corpus Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Cervical Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Uterine Corpus Cancer", "Stage IIIC Breast Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Uterine Corpus Cancer" ], "interventions": [ { "name": "Informational Intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 40, "start_date": "2015-08-01", "completion_date": "2016-10-31", "has_results": false, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-05-22T02:20:17.364Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania • Reading, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Reading", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03198286" }, { "nct_id": "NCT07460752", "title": "Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Locally Advanced Hormone Receptor-Positive Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 98, "start_date": "2026-03-24", "completion_date": "2029-09-26", "has_results": false, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-05-22T02:20:17.364Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07460752" }, { "nct_id": "NCT03968406", "title": "Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Female Reproductive System Neoplasm", "Recurrent Cervical Carcinoma", "Recurrent Endometrial Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Vaginal Carcinoma", "Stage IV Cervical Cancer AJCC v8", "Stage IV Fallopian Tube Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Primary Peritoneal Cancer AJCC v8", "Stage IV Uterine Corpus Cancer AJCC v8", "Stage IV Vaginal Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Fallopian Tube Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Primary Peritoneal Cancer AJCC v8", "Stage IVA Uterine Corpus Cancer AJCC v8", "Stage IVA Vaginal Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Fallopian Tube Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Primary Peritoneal Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8", "Stage IVB Vaginal Cancer AJCC v8" ], "interventions": [ { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Talazoparib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "RADIATION", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2019-09-26", "completion_date": "2027-10-01", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-05-22T02:20:17.364Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Houston, Texas", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03968406" }, { "nct_id": "NCT00525460", "title": "Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Fertility-Sparing Survey", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 16, "start_date": "2006-04", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2018-07-27", "last_synced_at": "2026-05-22T02:20:17.364Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00525460" }, { "nct_id": "NCT04678414", "title": "Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Endometrial Carcinoma", "Female Reproductive System Disorder", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Stage I Uterine Corpus Cancer AJCC v8", "Stage IA Cervical Cancer AJCC v8", "Stage IA Ovarian Cancer AJCC v8", "Stage IA Uterine Corpus Cancer AJCC v8", "Stage IA1 Cervical Cancer AJCC v8", "Stage IA2 Cervical Cancer AJCC v8", "Stage IB1 Cervical Cancer AJCC v8", "Stage IC Ovarian Cancer AJCC v8" ], "interventions": [ { "name": "Healthcare Activity", "type": "BEHAVIORAL" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 1410, "start_date": "2019-04-01", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-05-22T02:20:17.364Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04678414" } ] }